Search filters

List of works by Bartosz Chmielowski

A Phase I, open-label, dose escalation study of MGA271 in combination with ipilimumab in patients with B7-H3-expressing melanoma, squamous cell cancer of the head and neck or non-small cell lung cancer

scientific article published on 4 November 2015

A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas

scientific article

A phase 2 study of ontuxizumab, a monoclonal antibody targeting endosialin, in metastatic melanoma

scientific article published on 11 November 2017

A phase 2, multicenter, open-label study of sepantronium bromide (YM155) plus docetaxel in patients with stage III (unresectable) or stage IV melanoma

scientific article published on 23 December 2014

Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy

scientific article

Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma

scientific article

Altered Selection of CD4+ T Cells by Class II MHC Bound with Dominant and Low Abundance Self-Peptides

scientific article published on 01 December 2000

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

scientific article (publication date: 20 September 2014)

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines

scientific article

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

scientific article published on April 2016

Bilateral Subfoveal Neurosensory Retinal Detachment Associated With MEK Inhibitor Use for Metastatic Cancer

CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870,893.

scientific article published on October 2010

CRAF R391W is a melanoma driver oncogene

scientific article published on 08 June 2016

CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans

scientific article

Characterization of Postinfusion Phenotypic Differences in Fresh Versus Cryopreserved TCR Engineered Adoptive Cell Therapy Products

scientific article published on 21 February 2018

Characterizing the immune microenvironment of malignant peripheral nerve sheath tumor by PD-L1 expression and presence of CD8+ tumor infiltrating lymphocytes

scientific article published on 31 August 2016

Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial

scientific article

Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies

scientific article published on 17 August 2016

Clinical trial end points for assessing efficacy of novel therapies for soft-tissue sarcomas

scientific article published on September 2012

Combination of gemcitabine and docetaxel regresses both gastric leiomyosarcoma proliferation and invasion in an imageable patient-derived orthotopic xenograft (iPDOX) model.

scientific article published on 20 April 2017

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study

scientific article published on 15 July 2014

Combination treatment with recombinant methioninase enables temozolomide to arrest a BRAF V600E melanoma in a patient-derived orthotopic xenograft (PDOX) mouse model.

scientific article

Correlating animal and human phase Ia/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA.

scientific article

Cost-Effectiveness of Pembrolizumab Versus Ipilimumab in Ipilimumab-Naïve Patients with Advanced Melanoma in the United States

scientific article published on February 2017

Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma

scientific article published on 29 September 2009

Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032.

scientific article published on 20 April 2010

Do we need a different set of response assessment criteria for tumor immunotherapy?

scientific article

Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial

scientific article published on 22 March 2018

Endocrinopathies with use of cancer immunotherapies

scientific article

Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma

scientific article published on 18 March 2013

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

scientific article published on 15 March 2016

High response rate to PD-1 blockade in desmoplastic melanomas

scientific article published on 10 January 2018

How Should We Assess Benefit in Patients Receiving Checkpoint Inhibitor Therapy?

scientific article published in February 2018

Imaging of CTLA4 blockade-induced cell replication with (18)F-FLT PET in patients with advanced melanoma treated with tremelimumab

scientific article published on 11 February 2010

In the normal repertoire of CD4+ T cells, a single class II MHC/peptide complex positively selects TCRs with various antigen specificities

scientific article published on 01 January 1999

Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients

scientific article published on 31 January 2018

Infiltration of CD8 T Cells and Expression of PD-1 and PD-L1 in Synovial Sarcoma

scientific article published on 30 December 2016

Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure.

scientific article published on 4 November 2015

Insulin-like growth factor 1 receptor inhibitors: where do we come from? What are we? Where are we going?

scientific article published on 2 May 2014

Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it?

scientific article published on 11 May 2009

Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3.

scientific article published on 4 November 2015

Intra-lymph node prime-boost vaccination against Melan A and tyrosinase for the treatment of metastatic melanoma: results of a phase 1 clinical trial

scientific article

Ipilimumab: A First-in-Class T-Cell Potentiator for Metastatic Melanoma

scientific article published on 21 April 2013

Is there a role for single-agent BRAF inhibition in melanoma?

scientific article published in February 2017

KIT as a therapeutic target in metastatic melanoma

scientific article published on June 2011

LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer

scientific article published on 9 January 2018

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC.

scientific article published on 14 April 2017

Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab

scientific article published on 10 September 2015

Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression

scientific article published on 13 May 2015

Mature CD4+ T Cells Perceive a Positively Selecting Class II MHC/Peptide Complex in the Periphery

scientific article published on 01 March 2000

Modulation of cell signaling networks after CTLA4 blockade in patients with metastatic melanoma

scientific article (publication date: 15 September 2010)

Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma

scientific article

Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy

scientific article

Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma

scientific article published on 13 July 2016

Natural killer T cells in advanced melanoma patients treated with tremelimumab

scientific article

Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy

scientific article published on 08 March 2023

Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.

scientific article published on 11 May 2017

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

scientific article

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

scientific article

On the role of high- and low-abundance class II MHC–peptide complexes in the thymic positive selection of CD4+ T cells

scientific article published on 01 January 2000

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

scientific article

Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma

scientific article published on 01 December 2021

PD-1 Blockade Expands Intratumoral Memory T Cells

scientific article published on 19 January 2016

PD-1 blockade induces responses by inhibiting adaptive immune resistance

scientific article (publication date: 27 November 2014)

Patterns of sensitivity to a panel of drugs are highly individualised for undifferentiated/unclassified soft tissue sarcoma (USTS) in patient-derived orthotopic xenograft (PDOX) nude-mouse models

scientific article published on 23 August 2018

Predictors of Local Recurrence in Patients With Myxofibrosarcoma.

scientific article published on 20 June 2017

Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors

scientific article published on April 2012

Presentation of antagonist peptides to naive CD4+ T cells abrogates spatial reorganization of class II MHC peptide complexes on the surface of dendritic cells

scientific article

Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations

scientific article published on 30 November 2016

Prognostic and predictive biomarkers for the benefit of immunotherapy in patients with metastatic melanoma.

scientific article published in January 2016

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

scientific article published on January 2012

Recombinant methioninase (rMETase) is an effective therapeutic for BRAF-V600E-negative as well as -positive melanoma in patient-derived orthotopic xenograft (PDOX) mouse models

scientific article published on 12 December 2017

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

scientific article

Risk stratification of patients undergoing pulmonary metastasectomy for soft tissue and bone sarcomas

scientific article

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

scientific article (publication date: 11 July 2013)

Safety and efficacy of stereotactic body radiation therapy in the treatment of pulmonary metastases from high grade sarcoma

scientific article published on October 2013

Salmonella typhimurium A1-R targeting of a chemotherapy-resistant BRAF-V600E melanoma in a patient-derived orthotopic xenograft (PDOX) model is enhanced in combination with either vemurafenib or temozolomide.

scientific article published on 16 June 2017

Single-institution, multidisciplinary experience with surgical resection of primary chest wall sarcomas

scientific article published on March 2012

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

scientific article

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

scientific article

Targeting methionine with oral recombinant methioninase (o-rMETase) arrests a patient-derived orthotopic xenograft (PDOX) model of BRAF-V600E mutant melanoma: implications for chronic clinical cancer therapy and prevention.

scientific article published on 29 November 2017

The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics

scientific article published on 22 January 2014

The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations

scientific article

The specific T-cell response to antigenic peptides is influenced by bystander peptides.

scientific article published on January 2006

Tumor-Targeting Salmonella typhimurium A1-R Sensitizes Melanoma With a BRAF-V600E Mutation to Vemurafenib in a Patient-Derived Orthotopic Xenograft (PDOX) Nude Mouse Model

scientific article published on 20 January 2017

Tumor-targeting Salmonella typhimurium A1-R combined with temozolomide regresses malignant melanoma with a BRAF-V600E mutation in a patient-derived orthotopic xenograft (PDOX) model

scientific article

Vemurafenib-resistant BRAF-V600E-mutated melanoma is regressed by MEK-targeting drug trametinib, but not cobimetinib in a patient-derived orthotopic xenograft (PDOX) mouse model

scientific article published on 28 September 2016

Paulina is supported by:

About Paulina

Help